Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Praxair on NuCO2 Acquisition

Related PX
Benzinga's Top Initiations
Morgan Stanley Resumes Coverage On Praxair As Discussions With Linde Dissolve
Praxair CEO still open to merger with Linde, analyst says (Seeking Alpha)

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Praxair (NYSE: PX), and slightly raised its price target from $124.00 to $125.00.

Deutsche Bank noted, “Full but fair price at 9.6x '13E EBITDA. $0.10-plus accretive in '14E. Buy. We believe Praxair's acquisition of NuCO2 for $1.1B, or 9.6x '13E EBITDA, is sound as i) it is a strong strategic fit given Praxair's own competencies in distribution, logistics and productivity (not to mention Praxair is a supplier of CO2 to NuCO2), ii) the EBITDA multiple while full, is fair, given NuCO2's market leadership in US carbonation and robust (46%) EBITDA margins and iii) the midt-eens IRR for the acquisition is in-line with Praxair's large project backlog. While one-time costs will limit accretion to ~$0.02 in '13E, we estimate NuCO2 will be $0.10-plus, or 2%, accretive in '14. With 10%-plus EPS growth resuming in '14E and valuation an attractive 18.4x '13E EPS, Buy.”

Praxair closed on Tuesday at $110.58.

Latest Ratings for PX

Sep 2016Morgan StanleyInitiates Coverage onEqual-weight
Aug 2016CLSAMaintainsOutperform
Jul 2016CitigroupMaintainsNeutral

View More Analyst Ratings for PX
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (PX)

View Comments and Join the Discussion!